Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096837 | 0.87 | KCNN4 (0.47) | CES2CES1KIF11ALDH1A1GAA | |
| SCHEMBL13427144 | 0.87 | SMN1; SMN2 (0.43) | CES2CES1NPC1RAB9AALDH1A1 | |
| SCHEMBL27722753 | 0.85 | KCNN4 (0.45) | CES2CES1KIF11ALDH1A1GAA | |
| Phosphine SCHEMBL10642479 | 0.85 | KCNN4 (0.45) | CES2CES1KIF11ALDH1A1GAA | |
| SCHEMBL10606703 | 0.84 | MAPT (0.46) | CES2CES1KIF11NPC1RAB9A | |
| SCHEMBL829929 | 0.82 | ESR1 (0.52) | CES2CES1KIF11ALDH1A1KMT2A | |
| SCHEMBL21132837 | 0.82 | KIF11 (0.45) | CES2CES1KIF11NPC1RAB9A | |
| SCHEMBL10695316 | 0.81 | KIF11 (0.44) | CES2CES1KIF11NPC1RAB9A | |
| SCHEMBL3024596 | 0.81 | KIF11 (0.44) | CES2CES1KIF11NPC1RAB9A | |
| Acetic Acid SCHEMBL28848928 | 0.80 | KMT2A (0.44) | CES1CA2ALDH1A1KDM4EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-4720039-A2 | FORMULATIONS CONTAINING TRYPTAMINE DERIVATIVES AND USES THEREOF | Psilera Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024243488-A2 | FORMULATIONS CONTAINING TRYPTAMINE DERIVATIVES AND USES THEREOF | PSILERA INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | disclosed |
| EP-4017859-A1 | ALKYL QUARTERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | Caamtech, LLC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1719778-A1 | 3'-TERMINAL NUCLEOSIDE UNIT CONTAINING PHOSPHORAMIDITE | Japan Science and Technology Agency (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | POLR2H, POLN, RNGTT | CES2 3844/4885CES1 3261/4885KIF11 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.